You are here: Industry Insights > ICP-248

News List

Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress PharmaSources
June 14, 2024
Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2024 Hybrid Congress.
InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma PharmaSources
May 21, 2024
The first patient has been dosed in a clinical trial of the Company's BCL2 inhibitor, ICP-248, in combination with orelabrutinib as a first-line therapy for chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL) in China.
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma in China Chunhua Lu
March 13, 2024
BTK inhibitor orelabrutinib as first-line therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China.
InnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA PharmaSources
January 16, 2024
ICP-248 is a novel, orally bioavailable BCL2-selective inhibitor, which aims to treat hematologic malignancies as a monotherapy or in combination with other therapies.